Abstract:ABSTRACT Rabies continues to present a public health threat in most countries of the world. The most efficient way to prevent and control rabies is to implement vaccination programs for domestic animals. However, traditional inactivated vaccines used in animals are costly and have relatively low efficiency, which impedes their extensive use in developing countries. There is, therefore, an urgent need to develop single-dose and long-lasting rabies vaccines. However, little information is available regarding the mechanisms underlying immunological memory, which can broaden humoral responses following rabies vaccination. In this study, a recombinant rabies virus (RABV) that expressed murine interleukin-7 (IL-7), referred to here as rLBNSE-IL-7, was constructed, and its effectiveness was evaluated in a mouse model. rLBNSE-IL-7 induced higher rates of T follicular helper (Tfh) cells and germinal center (GC) B cells from draining lymph nodes (LNs) than the parent virus rLBNSE. Interestingly, rLBNSE-IL-7 improved the percentages of long-lived memory B cells (Bmem) in the draining LNs and plasma cells (PCs) in the bone marrow (BM) for up to 360 days postimmunization (dpi). As a result of the presence of the long-lived PCs, it also generated prolonged virus-neutralizing antibodies (VNAs), resulting in better protection against a lethal challenge than that seen with rLBNSE. Moreover, consistent with the increased numbers of Bmem and PCs after a boost with rLBNSE, rLBNSE-IL-7-immunized mice promptly produced a more potent secondary anti-RABV neutralizing antibody response than rLBNSE-immunized mice. Overall, our data suggest that overexpressing IL-7 improved the induction of long-lasting primary and secondary antibody responses post-RABV immunization. IMPORTANCE Extending humoral immune responses using adjuvants is an important method to develop long-lasting and efficient vaccines against rabies. However, little information is currently available regarding prolonged immunological memory post-RABV vaccination. In this study, a novel rabies vaccine that expressed murine IL-7 was developed. This vaccine enhanced the numbers of Tfh cells and the GC responses, resulting in upregulated quantities of Bmem and PCs. Moreover, we found that the long-lived PCs that were elicited by the IL-7-expressing recombinant virus (rLBNSE-IL-7) were able to sustain VNA levels much longer than those elicited by the parent rLBNSE virus. Upon reexposure to the pathogen, the longevous Bmem, which maintained higher numbers for up to 360 dpi with rLBNSE-IL-7 compared to rLBNSE, could differentiate into antibody-secreting cells, resulting in rapid and potent secondary production of VNAs. These results suggest that the expression of IL-7 is beneficial for induction of potent and long-lasting humoral immune responses.

Immunization with Recombinant Rabies Virus Expressing Interleukin-18 Exhibits Enhanced Immunogenicity and Protection in Mice

Recombinant Rabies Virus Expressing IFNα1 Enhanced Immune Responses Resulting in Its Attenuation and Stronger Immunogenicity.

Recombinant Rabies Virus Expressing IL-15 Enhances Immunogenicity Through Promoting the Activation of Dendritic Cells in Mice

Over-expression of IL-33 Enhances Rabies Virus Early Antigen Presentations and Cellular Immune Responses in Mice.

Recombinant rabies virus expressing IL-21 enhances immunogenicity through activation of T follicular helper cells and germinal centre B cells.

Expression of MIP-1α (CCL3) by a Recombinant Rabies Virus Enhances Its Immunogenicity by Inducing Innate Immunity and Recruiting Dendritic Cells and B Cells

Overexpression of Interleukin-7 Extends the Humoral Immune Response Induced by Rabies Vaccination

An Optimized HMGB1 Expressed by Recombinant Rabies Virus Enhances Immunogenicity Through Activation of Dendritic Cells in Mice

Immune Response of Inactivated Rabies Vaccine Inoculated via Intraperitoneal, Intramuscular, Subcutaneous and Needle-Free Injection Technology-Based Intradermal Routes in Mice

An inactivated recombinant rabies CVS-11 virus expressing two copies of the glycoprotein elicits a higher level of neutralizing antibodies and provides better protection in mice

Induction of Protective Immunity by Topic Application of A Recombinant Adenovirus Expressing Rabies Virus Glycoprotein

Immunization Against Rabies with Plant-Derived Antigen

A recombinant rabies virus encoding two copies of the glycoprotein gene confers protection in dogs against a virulent challenge.

A Recombinant Rabies Virus Expressing Fms-like Tyrosine Kinase 3 Ligand (flt3l) Induces Enhanced Immunogenicity in Mice

Recombinant Rabies Virus with the Glycoprotein Fused with a DC-binding Peptide is an Efficacious Rabies Vaccine.

Enhanced Immune Response to Rabies Viruses by the Use of a Liposome Adjuvant in Vaccines.

Immunogenicity and Antigenicity of the Ectodomain of Rabies Virus Glycoprotein Stably Expressed in HEK293T Cells

Efficiency of Live Attenuated and Inactivated Rabies Viruses in Prophylactic and Post Exposure Vaccination Against the Street Virus Strain

AAV-expressed G protein induces robust humoral and cellular immune response and provides durable protection from rabies virus challenges in mice

Recombinant Adeno-Associated Virus Serotype 9 AAV-RABVG Expressing a Rabies Virus G Protein Confers Long-Lasting Immune Responses in Mice and Non-Human Primates

A Novel Rabies Vaccine Expressing CXCL13 Enhances Humoral Immunity by Recruiting Both T Follicular Helper and Germinal Center B Cells.